Hims & Hers (HIMS), the millennial-skewed telehealth company, saw its stock tumble nearly 9% on Tuesday, as the company ...

Hims & Hers Health ( HIMS -7.38%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Hims & Hers Health (NYSE: HIMS) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach ...

Shares of Hims & Hers rose 7.59 percent on Wednesday to finish at $33.88 apiece as investors resorted to bargain-hunting following losses from the previous trading day, weighed down by a disappointing ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

AlphaQuest LLC cut its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 11.2% during the 4th ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

Hims & Hers app downloads surged 47% in February. Demand for GLP-1 weight-loss drugs is the most likely reason for the growth. But sales of such weight loss drugs are going away soon, and the ...